Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Texas judge rejects bid to block Kenvue's $398 million dividend and declines to restrict Tylenol marketing as the company f...
Kimberly-Clark is still "oversold after the Kenvue announcement," Jenny Van Leeuwen Harrington says, citing its 5% divi...
Argus Research analyst Taylor Conrad upgrades Kimberly-Clark (NASDAQ:KMB) from Hold to Buy and announces $120 price target.
The $48.7 billion Kimberly-Clark–Kenvue deal could reshape major consumer staples ETFs like XLP, VDC, and IYK.
TD Cowen analyst Robert Moskow maintains Kimberly-Clark (NASDAQ:KMB) with a Hold and lowers the price target from $130 to $112.
Morgan Stanley analyst Dara Mohsenian maintains Kimberly-Clark (NASDAQ:KMB) with a Equal-Weight and lowers the price target ...
Wells Fargo analyst Chris Carey maintains Kimberly-Clark (NASDAQ:KMB) with a Equal-Weight and lowers the price target from $...
